EDITORIAL COMMENT
Phosphodiesterase type 5 (PDE 5) inhibitors are currently first-line medical treatment for erectile dysfunction (ED). PDE 5 inhibitors are differentiated by safety-tolerability profiles and efficacy considerations, such as time to onset and duration of action. The choice of PDE 5 inhibitors in a man with ED is generally based on quality of life factors such as patient and partner satisfaction as well as efficacy and safety. In this randomized, double-blind, placebo controlled study, a total of 440 men with ED randomly assigned to placebo, or avanafil 100 or 200 mg. Avanafil group with 100 mg and 200 mg showed significantly higher rate of successful intercourse compared to placebo approximately 15 minutes after dosing. The adverse effects of avanafil were headache, upper respiratory tract infection, and nasal congestion. This study showed that avanafil treatment significantly improved erection sufficient for penetration within 15 minutes of dosing which is particularly well suited for ED treatment on demand with favorable side effects.
